enow.com Web Search

  1. Ad

    related to: targeted therapy for hodgkin's lymphoma prognosis by age

Search results

  1. Results from the WOW.Com Content Network
  2. Targeted therapy - Wikipedia

    en.wikipedia.org/wiki/Targeted_therapy

    Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy. [6] Co-targeted therapy involves the use of one or more therapeutics aimed at multiple targets, for example PI3K and MEK, in an attempt to generate a synergistic response [5] and prevent the development of drug resistance. [7] [8]

  3. Hodgkin lymphoma - Wikipedia

    en.wikipedia.org/wiki/Hodgkin_lymphoma

    Hodgkin lymphoma can be sub-classified by histological type. The cell histology in Hodgkin lymphoma is not as important as it is in non-Hodgkin lymphoma: the treatment and prognosis in classic Hodgkin lymphoma usually depends on the stage of disease rather than the histotype. [42]

  4. ABVD - Wikipedia

    en.wikipedia.org/wiki/ABVD

    As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. [citation needed] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1]

  5. Stanford V - Wikipedia

    en.wikipedia.org/wiki/Stanford_V

    Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...

  6. List of antineoplastic agents - Wikipedia

    en.wikipedia.org/wiki/List_of_antineoplastic_agents

    Germ cell tumours, squamous cell carcinoma, pancreatic cancer, non-Hodgkin's, pleural sclerosing and Hodgkin's lymphoma. Pulmonary toxicity, hypersensitivity, scleroderma and Raynaud's phenomenon. Bortezomib: IV, SC: Proteasome inhibitor. Multiple myeloma, mantle cell lymphoma and follicular lymphoma (orphan).

  7. MOPP (chemotherapy) - Wikipedia

    en.wikipedia.org/wiki/MOPP_(chemotherapy)

    MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen: ustargen (also known as mechlorethamine, chlormethine, mustine, nitrogen mustard, or MSD) ncovin (also known as Vincristine or VCR) rocarbazine (also known as Matulane or Natulan)

  8. High-dose chemotherapy - Wikipedia

    en.wikipedia.org/wiki/High-dose_chemotherapy

    HDC is known to be effective in treating types of cancer and has been found to enhance patient outcomes. This treatment method is commonly linked with blood cancers like multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. It is also used in solid tumors such as germ cell tumors and certain high risk or recurrent breast cancers.

  9. COPP (chemotherapy) - Wikipedia

    en.wikipedia.org/wiki/COPP_(chemotherapy)

    COPP is a chemotherapy regimen for treatment of Hodgkin disease, consisting of concurrent treatment with Cyclophosphamide, Oncovin, Procarbazine and Prednisone.. It contains less procarbazine than MOPP (procarbazine is given only for 10 days in cycle instead of 14), and the very toxic mechlorethamine, which is prone to giving severe neutropenia and to severely heighten the risk of secondary ...

  1. Ad

    related to: targeted therapy for hodgkin's lymphoma prognosis by age